Merck KGaA, Darmstadt, Germany, Wins European Investor Relations Award
- Company’s IR team voted No. 1 in the pharmaceutical sector by sell-side analysts
Darmstadt, Germany, April 25, 2016 – The Investor Relations (IR) team of Merck KGaA, Darmstadt, Germany, a leading science and technology company, was voted No. 1 in the prestigious "All-Europe Executive 2016 ranking" of Institutional Investor magazine in the category "Best Investor Relations Program – Nominated by the Sell Side" in the pharmaceutical sector. After last year’s third place in the same ranking, the Investor Relations team led by Constantin Fest, Head of Investor Relations, made another leap forward in the ranking.
"Congratulations to Constantin Fest and his team. I'm very pleased that our IR team has again been honored. This reflects our strong capital market orientation," said Marcus Kuhnert, Chief Financial Officer of Merck KGaA, Darmstadt, Germany. "We accept with pride the challenge to keep up our intensive and transparent communications with the financial markets," said Fest.
Altogether, more than 700 portfolio managers and 900 sell-side analysts participated in the survey. Important criteria include credibility, competency, expert knowledge, and objectivity in the communications with financial market participants. Other assessment criteria include timely information about future company developments as well as fast response times to queries.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.